Abstract
There are over 120 types of autoantibodies found in the blood of SLE patients against cellular and extracellular components in both their native and posttranslationally modified forms. In recent years, these autoantibodies have provoked interest as initiators of pathology and as biomarkers of disease activity. Often, the host antigens employed in lab-based and commercially developed immunoassays use non-human antigen or non-modified host antigen as a probe for autoantibodies. Here, we describe methods to posttranslationally modify host antigens, which better represent the antigen recognized by autoantibodies in vivo. This has implications in developing immunoassay with greater sensitivity and specificity.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Peters MJ, Van Halm VP, Nurmohamed MT, Damoiseaux J, Tervaert JW, Twisk JW et al (2008) Relations between autoantibodies against oxidized low-density lipoprotein, inflammation, subclinical atherosclerosis, and cardiovascular disease in rheumatoid arthritis. J Rheumatol 35:1495–1499
Shi J, Knevel R, Suwannalai P, Van Der Linden MP, Janssen GM, Van Veelen PA et al (2011) Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proc Natl Acad Sci U S A 108:17372–17377
Zendman AJ, Van Venrooij WJ, Pruijn GJ (2006) Use and significance of anti-CCP autoantibodies in rheumatoid arthritis. Rheumatology (Oxford) 45:20–25
Morgan PE, Sturgess AD, Davies MJ (2009) Evidence for chronically elevated serum protein oxidation in systemic lupus erythematosus patients. Free Radic Res 43:117–127
Morgan PE, Sturgess AD, Hennessy A, Davies MJ (2007) Serum protein oxidation and apolipoprotein CIII levels in people with systemic lupus erythematosus with and without nephritis. Free Radic Res 41:1301–1312
Eggleton P (2003) Stress protein-polypeptide complexes acting as autoimmune triggers. Clin Exp Immunol 134:6–8
Eggleton P, Haigh R, Winyard PG (2008) Consequence of neo-antigenicity of the ‘altered self’. Rheumatology (Oxford) 47:567–571
Bashir S, Harris G, Denman MA, Blake DR, Winyard PG (1993) Oxidative DNA damage and cellular sensitivity to oxidative stress in human autoimmune diseases. Ann Rheum Dis 52:659–666
Griffiths HR, Lunec J (1996) The C1q binding activity of IgG is modified in vitro by reactive oxygen species: implications for rheumatoid arthritis. FEBS Lett 388:161–164
Strollo R, Ponchel F, Malmstrom V, Rizzo P, Bombardieri M, Wenham CY et al (2013) Autoantibodies to posttranslationally modified type II collagen as potential biomarkers for rheumatoid arthritis. Arthritis Rheum 65:1702–1712
Ru JL, Wei H, Lu ZQ, Zhao CY, Li XF (2009) Role of DNA-associated autoantibodies to cell membrane in the diagnosis of juvenile systemic lupus erythematosus. Zhonghua Er Ke Za Zhi 47:820–823
Fragoso-Loyo H, Cabiedes J, Orozco-Narvaez A, Davila-Maldonado L, Atisha-Fregoso Y, Diamond B et al (2008) Serum and cerebrospinal fluid autoantibodies in patients with neuropsychiatric lupus erythematosus. Implications for diagnosis and pathogenesis. PLoS One 3:e3347
Hanly JG, Urowitz MB, Siannis F, Farewell V, Gordon C, Bae SC et al (2008) Autoantibodies and neuropsychiatric events at the time of systemic lupus erythematosus diagnosis: results from an international inception cohort study. Arthritis Rheum 58:843–853
Heinlen LD, Mcclain MT, Merrill J, Akbarali YW, Edgerton CC, Harley JB et al (2007) Clinical criteria for systemic lupus erythematosus precede diagnosis, and associated autoantibodies are present before clinical symptoms. Arthritis Rheum 56:2344–2351
Doyle HA, Mamula MJ (2001) Post-translational protein modifications in antigen recognition and autoimmunity. Trends Immunol 22:443–449
Morgan PE, Sturgess AD, Davies MJ (2005) Increased levels of serum protein oxidation and correlation with disease activity in systemic lupus erythematosus. Arthritis Rheum 52:2069–2079
Ohmori H, Oka M, Nishikawa Y, Shigemitsu H, Takeuchi M, Magari M et al (2005) Immunogenicity of autologous IgG bearing the inflammation-associated marker 3-nitrotyrosine. Immunol Lett 96:47–54
Birnboim HC, Lemay AM, Lam DK, Goldstein R, Webb JR (2003) Cutting edge: MHC class II-restricted peptides containing the inflammation-associated marker 3-nitrotyrosine evade central tolerance and elicit a robust cell-mediated immune response. J Immunol 171:528–532
Nettleman MD (1988) Receiver operator characteristic (ROC) curves. Infect Control Hosp Epidemiol 9:374–377
Acknowledgements
This work was supported by an Arthritis Research UK grant (No. 17966), the Torbay Medical Research Fund and Northcott Devon Medical Foundation and a travel fellowship from the Alberta Innovates Health Solutions.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media, New York
About this protocol
Cite this protocol
Ryan, B.J., Eggleton, P. (2014). Detection and Characterization of Autoantibodies Against Modified Self-Proteins in SLE Sera After Exposure to Reactive Oxygen and Nitrogen Species. In: Eggleton, P., Ward, F. (eds) Systemic Lupus Erythematosus. Methods in Molecular Biology, vol 1134. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-0326-9_12
Download citation
DOI: https://doi.org/10.1007/978-1-4939-0326-9_12
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-0325-2
Online ISBN: 978-1-4939-0326-9
eBook Packages: Springer Protocols